The United States Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Piramal Pharma’s manufacturing facility located at Lexington (Kentucky, USA). The inspection has now been successfully closed by the USFDA.
Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries.